| GPCR Library |
8532 compounds
For cherry-picking
Update: 2020-07 |
The file contains all available GPCR compounds selected from our Signature &
BioDesign Libraries.
|
|
| Lipid GPCR Library |
2344 compounds
Update: 2020-07 |
The file contains ALL Lipid GPCR compounds for cherry-picking.
|
|
Peptide GPCR Library
(Macrocycles) |
6285 compounds
Release: 2020-07 |
The file contains ALL Peptidergic GPCR macrocycles for cherry-picking.
|
|
SL#014
Peptide GPCRs,
SST4R agonists |
80 compounds
Pre-Plated Set
Release: 2016 |
ASINEX's GPCR screening platform including an SST4 binding assay, SST4 GTPγS assay,
and SST4 cell functional assays, has identified several potent modulators of
SST4R.
|
|
SL#078
Sympathomimetics
chemical probes |
80 compounds
Pre-Plated Set
Release: 2017 |
Asinex has developed several analogs of Propranolol - first clinically successful
sympathomimetic, containing the characteristic 3-amino-2-hydroxypropanol
fragment.
|
|
SL#088
Free Fatty Acid Receptor
(FFAR) Regulators |
80 compounds
Pre-Plated Set
Release: 2018 |
Known small molecule agonists of FFA receptors share some common pharmacophoric
features, such as a carboxylic acid moiety attached directly or via an aliphatic
tail to an aromatic core. A pharmacophore search through ASINEX’s compound
collection identified several hits that can be explored for FFA research and drug
discovery.
|
|
SL#089
Dopamine receptor type 2
(DRD2) inhibitors |
80 compounds
Pre-Plated Set
Release: 2018 |
Several recent studies demonstrated that dopamine receptors D2 are associated with
tumorigenesis. Some antipsychotic drugs showed anti neoplastic effects on human
cancers as adjuvants enhancing the effi¬cacy of anticancer therapy in breast and
colon cancer cell lines. A pharmacophore search through ASINEX’s compound collection
identified several molecules that can be explored for GPCR research and anticancer
drug discovery.
|
|
SL#090
κ-Opioid receptor
(KOR) agonists |
80 compounds
Pre-Plated Set
Release: 2018 |
Recent report shows a novel chemical series of KOR agonists based on a triazole
scaffold. The lead compound Triazole 1.1 was tested in vivo and demonstrated a
preservation of the analgesic properties with no signs of the sedating or dysphoric
effects of typical KOR agonists.
Analogs of the reported triazole lead series
were included into this library.
|
|
